These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

887 related articles for article (PubMed ID: 26818199)

  • 21. p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors.
    Chiche A; Moumen M; Romagnoli M; Petit V; Lasla H; Jézéquel P; de la Grange P; Jonkers J; Deugnier MA; Glukhova MA; Faraldo MM
    Oncogene; 2017 Apr; 36(17):2355-2365. PubMed ID: 27775073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor shedding and metastatic progression after tumor excision in patient-derived orthotopic xenograft models of triple-negative breast cancer.
    Razmara AM; Sollier E; Kisirkoi GN; Baker SW; Bellon MB; McMillan A; Lemaire CA; Ramani VC; Jeffrey SS; Casey KM
    Clin Exp Metastasis; 2020 Jun; 37(3):413-424. PubMed ID: 32335861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
    Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
    Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
    Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Wahba B; Anbalagan M; Rowan B; Abazeed ME; Bunnell BA; Moroz K; Miele L; Rhodes LV; Jones SD; Martin EC; Collins-Burow BM; Burow ME
    BMC Cancer; 2019 Mar; 19(1):205. PubMed ID: 30845999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis.
    Yuan W; Goldstein LD; Durinck S; Chen YJ; Nguyen TT; Kljavin NM; Sokol ES; Stawiski EW; Haley B; Ziai J; Modrusan Z; Seshagiri S
    Breast Cancer Res; 2019 Dec; 21(1):152. PubMed ID: 31881983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer.
    Chen HA; Chang YW; Tseng CF; Chiu CF; Hong CC; Wang W; Wang MY; Hsiao M; Ma JT; Chen CH; Jiang SS; Wu CH; Hung MC; Huang MT; Su JL
    Ann Surg Oncol; 2015 Mar; 22(3):889-98. PubMed ID: 25212833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 functional deficiency in human colon cancer cells promotes fibroblast-mediated angiogenesis and tumor growth.
    Hayashi Y; Tsujii M; Kodama T; Akasaka T; Kondo J; Hikita H; Inoue T; Tsujii Y; Maekawa A; Yoshii S; Shinzaki S; Watabe K; Tomita Y; Inoue M; Tatsumi T; Iijima H; Takehara T
    Carcinogenesis; 2016 Oct; 37(10):972-984. PubMed ID: 27520561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
    Cerqueira OL; Truesdell P; Baldassarre T; Vilella-Arias SA; Watt K; Meens J; Chander H; Osório CA; Soares FA; Reis EM; Craig AW
    Oncotarget; 2015 Apr; 6(11):9397-408. PubMed ID: 25823823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-targeting adenovirus OBP-401 inhibits primary and metastatic tumor growth of triple-negative breast cancer in orthotopic nude-mouse models.
    Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
    Oncotarget; 2016 Dec; 7(51):85273-85282. PubMed ID: 27863373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung.
    Tawara K; Bolin C; Koncinsky J; Kadaba S; Covert H; Sutherland C; Bond L; Kronz J; Garbow JR; Jorcyk CL
    Breast Cancer Res; 2018 Jun; 20(1):53. PubMed ID: 29898744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.
    Turner TH; Alzubi MA; Sohal SS; Olex AL; Dozmorov MG; Harrell JC
    Breast Cancer Res Treat; 2018 Jul; 170(2):221-234. PubMed ID: 29532339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer.
    Johnstone CN; Smith YE; Cao Y; Burrows AD; Cross RS; Ling X; Redvers RP; Doherty JP; Eckhardt BL; Natoli AL; Restall CM; Lucas E; Pearson HB; Deb S; Britt KL; Rizzitelli A; Li J; Harmey JH; Pouliot N; Anderson RL
    Dis Model Mech; 2015 Mar; 8(3):237-51. PubMed ID: 25633981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
    Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
    Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
    Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
    Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
    [No Abstract]   [Full Text] [Related]  

  • 36. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
    Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
    Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib.
    Takahashi F; Chiba N; Tajima K; Hayashida T; Shimada T; Takahashi M; Moriyama H; Brachtel E; Edelman EJ; Ramaswamy S; Maheswaran S
    Oncogene; 2011 Jul; 30(27):3084-95. PubMed ID: 21339742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Jin K; Pandey NB; Popel AS
    Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
    Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
    Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.